Stock AnalizNeurocrine Biosciences (NBIX) earnings for the quarter ended September 2026: EPS beats estimates
Neurocrine Biosciences reported results for the quarter ended September 2026 on November 2, 2026. Adjusted earnings per share came in at $3.29 against the analysts’ average forecast of $2.75, a beat of 19.8%.
Revenue for the quarter was $1.12 billion, up 41.2% from $795 million in the same quarter a year earlier.
The market’s verdict: the stock rose 12.8% on the first trading day after the report.
The last four quarters
Neurocrine Biosciences has beaten the analysts’ EPS forecast in 3 of the last 4 quarters.
| Quarter | EPS | Forecast | Surprise | Revenue growth | Price reaction |
|---|---|---|---|---|---|
| Sep 2026 | $3.29 | $2.75 | +19.8% | +41% | +12.8% |
| Jun 2026 | $2.85 | $1.96 | +45.4% | +39% | −7.7% |
| Mar 2026 | $1.94 | $1.70 | +14.4% | +42% | +9.7% |
| Dec 2025 | $1.88 | $2.30 | −18.1% | +28% | −10.6% |
What comes next
Analysts expect EPS of $2.77 for the next quarter on average and $10.59 for the fiscal year ending December 31, 2026.
The average analyst price target is $208.11, 24% above the current price of $167.40.
Valuation and score
Neurocrine Biosciences scores 3.0 out of 5 overall on Stock Analiz (good, with some weak spots), trades at a trailing P/E of about 24.8, and its intrinsic value under moderate assumptions is about 53% above the current market value. Full Neurocrine Biosciences analysis with 10 years of financials
Frequently asked questions
What was Neurocrine Biosciences’s EPS for the quarter ended September 2026?
$3.29 adjusted per share, against an analyst consensus of $2.75.
How much revenue did Neurocrine Biosciences report?
$1.12 billion, up 41.2% year over year.
More
This report was written automatically from the published numbers within hours of the release. It is information, not investment advice.